查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197362

腎功能檢測市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Kidney Function Tests Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內，腎功能檢測市場的複合年增長率預計為 5.62%。

COVID-19 隨著疾病的進展影響患者的腎功能，因此大流行對腎功能檢測市場產生了重大影響。 根據 2020 年 11 月發表的一項題為“Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19”的研究，超過 40% 的 COVID-19 住院患者有蛋白尿和血尿等症狀。據說觀察到腎功能障礙的症狀。 此外，根據一項名為“新生兒和兒科的 COVID-19 感染”的研究，“COVID-19 感染的臨床特徵。據報導，19 引起的尿失禁在中度至重度患者中很常見。 在兒童中，已報告輕度 COVID-19 患者接觸過 COVID-19。 發病後第1天至第52天確認尿路感染。 這種情況在大流行期間對市場增長率產生了顯著影響。

此外，慢性腎髒病的增加，糖尿病、高血壓等導致腎臟損害的基礎疾病的增加，腎功能診斷方法意識的提高，診斷設備和工具的技術進步等因素，推動市場的增長，這是一個激勵因素。

糖尿病和高血壓被認為是導致全球慢性腎髒病負擔增加的主要因素。 糖尿病患者數量的增加最終將影響預測期內的市場增長。 例如，根據 2021 年第 10 版國際糖尿病地圖集，5.37 億成年人（20-79 歲）患有糖尿病，其中大約十分之一患有糖尿病。 這一數字預計到 2030 年將增加到 6.43 億，到 2045 年將增加到 7.83 億。

此外，市場參與者正在採取各種策略，例如產品發布、產品開發、合作夥伴關係、收購、整合和擴展，以最大限度地擴大其在全球的地理覆蓋範圍。 例如，2020 年 8 月，RenalytixAI 獲得美國食品和藥物管理局 (FDA) 批准用於新的 KidneyIntelX 測試。 人工智能驅動的臨床試驗旨在識別和改善 2 型糖尿病和快速進展的腎臟疾病患者的臨床管理。 預計技術先進產品的出現將在預測期內進一步推動市場增長。

因此，上述因素可能會對市場的增長產生積極影響。 然而，診斷程序的高成本和嚴格的法規預計將在不久的將來阻礙腎功能檢測市場的增長。

腎功能檢測的市場趨勢

在腎功能檢測市場，試紙板塊有望佔據主要市場份額

量油尺是一種塑料棒，上面附有一系列化學物質。 將此試紙浸入尿液中，當色帶變色時，表明存在異常物質，例如蛋白質、血液、發紅、細菌和糖分。 這使我們能夠識別廣泛的腎臟和泌尿系統問題，例如慢性腎臟疾病、急性腎損傷、膀胱疾病和腎結石。

美國國立衛生研究院 (NIH) 報告說，大多數患有嚴重 COVID-19 急性腎損傷 (AKI) 的患者在康復後繼續進行下腎臟治療。 2022 年 2 月發表的一項題為“使用試紙尿液分析預測 COVID-19 患者腎臟損傷的發展”的研究發現，試紙尿液分析中的蛋白尿和血尿水平與住院期間的 COVID-19 相關。已發現它可用於預測 19 名患者的 AKI 和腎臟替代治療 (RRT)。 同樣，美國國家腎臟基金會於 2020 年 3 月發布的一份報告指出，住院的 COVID-19 患者患嚴重腎損傷 (AKI) 的風險增加，這可能導致重病和死亡。我來了。 在一項類似的研究中，與 2019 年同時發生 AKI 的非 COVID 患者相比，2020 年 3 月 11 日至 4 月 26 日住院的 COVID-19 患者發生了 AKI。發生這種情況的機率翻了一番，計算為 56.9% 對 25.1% ％， 分別。 因此，由於易於診斷和產品可用性，預計 COVID-19導致的腎衰竭和慢性腎衰竭發病率上升將在預測期內推動該細分市場的增長。

此外，2021 年 8 月，總部位於西雅圖的 ID Genomics (IDG) 將發明一種基於試紙的檢測方法，以同時識別 SARS-CoV2 中的多個基因突變，而國家衛生部已從美國國家研究院獲得 300,000 美元的資助衛生部 (NIH)。

此外，政府對腎功能障礙的舉措和投資的更多關注以及腎臟疾病的新療法將促進這一細分市場的增長。 例如，2020 年 1 月，瑞典的 Elypta AB 籌集了 700 萬美元用於尿癌篩查測試。

因此，由於上述因素，該細分市場在預測期內可能會出現增長。

北美主導市場，預計在預測期內將繼續保持這一勢頭

北美地區的市場增長是由改善的醫療保健基礎設施、增加的尿路感染髮病率以及更廣泛使用的診斷測試推動的。

冠狀病毒正在對該地區產生重大影響，尤其是在美國。 2020 年，約翰霍普金斯大學腎髒病學系建議應對與 COVID-19 相關的腎臟損傷進行檢測，以確保腎功能恢復正常。 因此，預計該地區 COVID-19負擔的增加將增加對腎臟檢測的需求，從而對市場增長產生積極影響。 此外，根據衛生資源服務局的數據，到 2022 年 2 月，美國將進行大約 26,640 例腎臟移植手術。 如此大量的移植導致需要進行移植後腎功能檢測以檢測正常腎功能，從而推動市場增長。

此外，腎臟疾病負擔的增加及其根本原因預計將推動北美市場的增長。 例如，根據腎臟基金會發布的 2020 年報告，加拿大約有 400 萬人患有腎臟疾病，其中 46% 的新病例年齡在 65 歲以下。 自 2009 年以來，患有終末期腎病的人數增加了 35%。 因此，該地區這些疾病的高負擔預計會增加對腎功能檢測的需求。

此外，2022 年 7 月，bioMerieux 獲得了美國食品和藥物管理局的許可，其創新的 VIDAS NEPHROCHECK 檢測方法可檢測有急性腎損傷 (AKI) 風險的患者的腎臟壓力。 該地區新產品的推出和尿液分析的不斷進步正在推動市場增長。

因此，由於上述因素，預計北美地區的市場增長。

腎功能檢測市場競爭對手分析

腎功能檢測市場的競爭是分散的，由幾家大公司組成。 從市場份額的角度來看，一些主要參與者目前主導著市場。 目前主導市場的公司包括 F. Hoffmann-La Roche Ltd.、ACON Laboratories Inc.、77 Elektronika Kft、Nova Biomedical 和 Quest Diagnostics。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 慢性腎髒病患病率上升
    • 提高對腎臟正常功能診斷方法的認識
    • 診斷機器和儀器的技術進步
  • 市場製約因素
    • 診斷程序的高成本
    • 嚴格監管
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模 - 百萬美元）

  • 按產品類型
    • 滴管
    • 一次性的
    • 試劑
  • 按測試類型
    • 尿液分析試劑
      • 尿蛋白測試
      • 用於測量肌酐清除率
      • 微量白蛋白測量
    • 驗血
      • 血清肌酐測量
      • 腎小球濾過率測試
      • 血尿素氮測量
  • 最終用戶
    • 醫院和診所
    • 診斷機構
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • F.Hoffmann-La Roche Ltd
    • URIT Medical Electronic Co. Ltd
    • Arkray Inc.
    • Abbott Laboratories
    • Nova Biomedical
    • Sysmex Corporation
    • ACON Laboratories Inc.
    • 77 Elektronika Kft
    • Randox Laboratories
    • Quest Diagnostics
    • bioMerieux SA
    • Laboratory Corporation of America Holdings

第7章 市場機會今後動向

簡介目錄
Product Code: 68015

The Kidney Function Tests Market is expected to register a CAGR of 5.62% during the forecast period, 2022-2027.

The pandemic has significantly impacted the kidney function tests market, as COVID-19 affected the patients' kidney function with the disease progression. According to a study titled "Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19" published in November 2020, more than 40% of admitted patients with COVID-19 showed symptoms of abnormal kidney function, such as albuminuria or hematuria. Furthermore, according to a study titled "Clinical Characteristics of COVID-19 Infection in Newborns and Pediatrics: A Systematic Review" published in April 2020, in adult patients, COVID-19 urinary incontinence was commonly found in patients with moderate to severe conditions. In children, exposure to COVID-19 has been reported among those who suffer from a mild form of COVID-19. From the onset of the disease, urinary tract infections were identified from day 1 to day 52. Thus, such instances notably impacted the growth rate of the market over the pandemic phase.

Furthermore, some of the factors driving the growth of the market include an increase in chronic kidney disease; the growing prevalence of underlying conditions such as diabetes and hypertension leading to kidney disorders; an increase in awareness about diagnostic methods for kidney function; and technological advances in diagnostic equipment and tools.

Diabetes and high blood pressure are considered major factors responsible for the growing burden of chronic kidney disease worldwide. Growing cases of diabetes will ultimately impact the growth of the market over the forecast period. For instance, according to the International Diabetes Atlas tenth edition in 2021, 537 million adults (20-79 years) were living with diabetes, approximately 1 in 10 individuals. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

Additionally, market players embrace a variety of strategies such as product launches, product developments, collaborations, acquisitions, integrations, and expansion to maximize their geographical reach worldwide. For example, in August 2020, RenalytixAI received approval from the United States Food and Drug Administration (FDA) for its new KidneyIntelX test. AI-enabled clinical trials are designed to identify and improve the clinical management of patients with type 2 diabetes and rapidly progressive kidney disease. The emergence of technologically advanced products is expected to further boost the market's growth over the forecast period.

Thus, the aforesaid factors are likely to have a positive impact on the market's growth. However, the high cost of diagnostic procedures and strict regulations are expected to hamper the kidney function tests market's growth in the near future.

Kidney Function Tests Market Trends

Dipstick Segment is Expected to Hold a Major Market Share in the Kidney Function Tests Market

The dipstick is a type of plastic stick that has a chemical line on it in the form of lines. The dipstick is dipped in urine, and when the color of the ribbon changes, it indicates the presence of abnormal substances such as protein, blood, redness, bacteria, and sugar. This helps to identify a range of kidney and urinary problems, such as chronic kidney disease, acute kidney injuries, bladder diseases, and kidney stones, among others.

The National Institute of Health (NIH) reported that most patients with serious COVID-19 acute kidney injury (AKI) complications are still working on their lower kidneys after recovery. According to the study titled "Using dipstick urinalysis to predict the development of kidney damage in patients with COVID-19" published in February 2022, the levels of proteinuria and hematuria in dipstick urine analysis can be used to predict AKI and renal replacement therapy (RRT) in hospitalized COVID-19 patients. Likewise, a report published by the National Kidney Foundation Inc. in March 2020 stated that hospitalized people with COVID-19 were at a higher risk of serious kidney injury (AKI), which could lead to serious illness and even death. A similar study found that patients with COVID-19, who were hospitalized between March 11 and April 26, 2020, were twice as likely to develop AKI compared to non-COVID patients who developed AKI simultaneously in 2019, which was calculated at 56.9% compared to 25.1%, respectively. Therefore, an increase in the incidence of kidney failure and chronic kidney failure due to COVID-19 is expected to promote the segment's growth during the forecast period due to ease of diagnosis and availability of products.

Moreover, in August 2021, ID Genomics (IDG), a Seattle-based company, invented a dipstick-based assay for the simultaneous identification of a large number of genetic variants of SARS-CoV2 and received a grant of USD 300,000 from the National Institute of Health (NIH).

Furthermore, rising government efforts to address improper kidney functions, growing investments, and newer treatments for kidney disease are at the forefront, which will in turn bolster the segment's growth. For example, in January 2020, Sweden's Elypta AB collected a USD 7.0 million fund for a urine cancer screening test.

Therefore, due to these abovementioned factors, the segment may witness growth during the forecast period.

North America Dominates the Market and is Expected to Continue the Same Over the Forecast Period

Some of the factors driving the growth of the market in the North American region include better health care infrastructure, an increase in urinary tract infections, and more widely available diagnostic tests.

The coronavirus has had a significant impact in the region, particularly in the United States. The Johns Hopkins Division of Nephrology, in 2020, suggested that COVID-19-related kidney damage should be followed by tests to ensure kidney function returns to normal. Therefore, the growing burden of COVID-19 in the region is expected to increase the need for kidney tests, thereby positively impacting the market's growth. Moreover, according to the Health Resources & Services Administration, in February 2022 in the United States, about 26,640 kidney transplants were performed. Such a high number of transplants creates the need for kidney function tests post-transplantation procedures to detect the proper functioning of the kidneys and thus drives the growth of the market.

Moreover, the growing burden of kidney diseases and their underlying causes are anticipated to boost market growth in North America. For instance, in 2020, a report published by the Kidney Foundation stated that around 4 million people have kidney disease in Canada, of which 46% of new patients are under the age of 65. In addition, the number of people living with end-stage kidney disease has grown by 35% since 2009. This significant burden of these diseases in the region is expected to augment the demand for kidney function tests.

Additionally, in July 2022, bioMerieux received United States Food and Drug Administration clearance for the innovative VIDAS NEPHROCHECK assay to detect kidney stress in patients at risk of acute kidney injury (AKI). The introduction of new products and the growing advances in urine analysis in the region are boosting the market's growth.

Therefore, owing to the abovementioned factors, the market is expected to grow in the North American region.

Kidney Function Tests Market Competitor Analysis

The Kidney Function Tests Market is fragmented in terms of competition and consists of several major players. In terms of market share, a few major players are currently dominating the market. Some companies currently dominating the market include F.Hoffmann-La Roche Ltd., ACON Laboratories Inc., 77 Elektronika Kft, Nova Biomedical, and Quest Diagnostics.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Chronic Kidney Diseases
    • 4.2.2 Increasing Awareness about the Diagnostic Methods for the Proper Functioning of the Kidney
    • 4.2.3 Technological Advancements in Diagnostic Machinery and Tools
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Diagnostic Procedures
    • 4.3.2 Stringent Regulations Norms
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Dipsticks
    • 5.1.2 Disposables
    • 5.1.3 Reagents
  • 5.2 By Test Type
    • 5.2.1 Urine Tests
      • 5.2.1.1 Urine Protein Tests
      • 5.2.1.2 Creatinine Clearance Tests
      • 5.2.1.3 Microalbumin Tests
    • 5.2.2 Blood Tests
      • 5.2.2.1 Serum Creatinine Tests
      • 5.2.2.2 Glomerular Filtration Rate Tests
      • 5.2.2.3 Blood Urea Nitrogen Tests
  • 5.3 By End User
    • 5.3.1 Hospitals and Clinics
    • 5.3.2 Diagnostic Laboratories
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F.Hoffmann-La Roche Ltd
    • 6.1.2 URIT Medical Electronic Co. Ltd
    • 6.1.3 Arkray Inc.
    • 6.1.4 Abbott Laboratories
    • 6.1.5 Nova Biomedical
    • 6.1.6 Sysmex Corporation
    • 6.1.7 ACON Laboratories Inc.
    • 6.1.8 77 Elektronika Kft
    • 6.1.9 Randox Laboratories
    • 6.1.10 Quest Diagnostics
    • 6.1.11 bioMerieux SA
    • 6.1.12 Laboratory Corporation of America Holdings

7 MARKET OPPORTUNITIES AND FUTURE TRENDS